Frontline Zejula maintenance therapy decreased the risk of disease progression or death in patients with newly diagnosed ovarian cancer. Upfront maintenance therapy with Zejula (niraparib) decreased ...
Between June 1998 and August 2002, 114 patients who had received previous chemotherapy for indolent non-Hodgkin's lymphoma were treated with a standard 4-week course of rituximab. Patients with ...
SAN FRANCISCO — Maintenance treatment with capecitabine (Xeloda) and bevacizumab (Avastin) significantly delayed disease progression, compared with observation, in patients with metastatic colorectal ...
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, ...
TUKYSA, trastuzumab, and pertuzumab reduced the risk of disease progression or death by 36% compared to trastuzumab and pertuzumab alone in Phase 3 HER2CLIMB-05 study The combination demonstrated a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback